Perimenopause — the years-long transition before the final menstrual period — affects hormone levels, sleep, mood, and cycle regularity for most women, but the experience varies so widely that the term acts as a description of a life stage rather than a condition to be diagnosed or treated in every case.
What perimenopause actually is
Perimenopause begins when ovarian hormone production becomes more variable, typically in the mid-to-late 40s, and ends 12 months after the final period. The average duration is around four years, but some women experience symptoms for a decade while others notice almost nothing. The National Institute for Health and Care Excellence (NICE) defines perimenopause as the period of hormonal change leading up to menopause, noting that symptoms — not blood test results — are the primary basis for clinical decisions about treatment.
The shift in oestrogen and progesterone is not a steady decline; it is erratic. Some months produce normal ovulatory cycles; others do not. This unpredictability is what makes perimenopause harder to characterise than menopause itself, and why the symptom profile can change from one month to the next.
The symptoms worth knowing
The most commonly reported perimenopausal symptoms include changes in menstrual cycle length and flow, hot flushes and night sweats, sleep disruption, mood changes (particularly irritability and low mood), vaginal dryness, and cognitive complaints often described as brain fog. A 2024 Lancet review by Hickey and colleagues mapped the evidence across multiple domains and concluded that symptom severity is shaped not just by hormone levels but by psychological, social, and contextual factors — many of which are modifiable. The review argued for an empowerment model that goes beyond treating individual symptoms to support women through the transition as a whole.
Sleep disruption is often the earliest signal, preceding hot flushes by several years in some women. The NHS notes that perimenopausal symptoms vary from minor to severe and can be experienced over short or long time periods, which makes tracking them over several months more useful than reacting to a single bad week.
When testing helps and when it does not
Blood tests for follicle-stimulating hormone (FSH) and oestradiol are often requested, but NICE advises that in women over 45 with typical symptoms, perimenopause and menopause can be identified on symptoms alone, without laboratory tests. Testing is most useful for women under 40, those with atypical symptoms, or when considering hormone therapy. The natural variability of hormone levels during perimenopause means a single blood draw can be misleading — FSH and oestradiol fluctuate from week to week, and even from day to day.
NICE specifically recommends against using anti-Müllerian hormone, inhibin A, inhibin B, oestradiol, antral follicle count, or ovarian volume to identify perimenopause or menopause in women aged 45 or over. The tests add noise, not clarity.
For women under 40, testing serves a different purpose. Premature ovarian insufficiency (POI) affects approximately 1% of women in this age group, and symptoms alone are not sufficient to distinguish POI from other causes of menstrual irregularity. NICE recommends measuring FSH on two occasions, four to six weeks apart, when POI is suspected, alongside a clinical assessment that includes a full menstrual history. In this context, testing clarifies rather than confuses — but the key is that the indication is different from the routine testing discouraged in older women.
What the evidence says about treatment
For women whose symptoms significantly affect quality of life, menopausal hormone therapy (MHT, formerly HRT) is the most effective option for vasomotor symptoms and has some evidence supporting its use for mood and sleep. NICE recommends offering HRT to people with vasomotor symptoms and, when discussing options, tailoring the information about benefits and risks to the person’s age, individual circumstances, and potential risk factors. For most women under 60 who start MHT within ten years of menopause, the benefits for symptom relief outweigh the risks.
Non-hormonal options include menopause-specific cognitive behavioural therapy, which NICE recommends for vasomotor symptoms, sleep problems, and depressive symptoms — either alongside HRT or for women who prefer not to take hormones. Lifestyle factors — particularly resistance training, protein intake, and sleep hygiene — can help manage weight gain, muscle loss, and sleep disruption during the transition, though the evidence for lifestyle as a standalone treatment for vasomotor symptoms is modest.
How perimenopause affects metabolic health
The metabolic shifts that accompany the perimenopausal transition deserve attention in their own right. Declining oestrogen is linked to reduced insulin sensitivity, and many women notice a redistribution of body fat toward the abdomen — even when overall weight remains stable. This is not simply about calorie intake; it reflects changes in how the body partitions and stores energy, driven partly by the hormonal fluctuations that characterise the transition.
Resistance training becomes particularly relevant here. It improves insulin sensitivity and helps preserve lean mass, which naturally declines during this period. The practical implication is that perimenopause may be a time to adjust nutritional priorities — specifically ensuring adequate protein intake to support muscle protein synthesis — rather than turning to restrictive diets that can compound metabolic stress. NICE’s guideline on menopause also acknowledges the importance of discussing lifestyle changes, including weight-bearing exercise and healthy eating, as part of a comprehensive approach to care.
What this means in practice
- Perimenopause is a normal life stage, not a medical condition that always requires treatment.
- Track your symptoms — particularly sleep quality, cycle length, hot flush frequency, and mood — for at least three months before seeking medical advice, unless symptoms are severe. A simple diary or a period-tracking app can capture the patterns that a single GP visit might miss.
- Blood tests are not always necessary for women over 45 with typical symptoms, and they can be misleading if interpreted without clinical context.
- If symptoms interfere with daily life, discuss MHT or non-hormonal options such as CBT with a GP or menopause specialist.
- Resistance training, adequate protein, and consistent sleep timing are practical levers that support muscle, metabolism, and mood during the transition.
- Perimenopause affects metabolism, not just symptoms. Prioritising resistance training and protein intake can help maintain insulin sensitivity and lean mass through the transition.
What we don’t know
The evidence on perimenopause still has significant gaps. Most research has focused on women in their 50s who have reached menopause, meaning the perimenopausal period itself is relatively understudied. The Lancet review authors noted that the experience of menopause varies substantially depending on individual, social, and contextual factors, but current models do not explain why some women have a difficult transition while others have minimal symptoms. The relationship between perimenopausal hormonal changes and long-term health outcomes — cardiovascular risk, cognitive decline, bone density — is not yet fully mapped, particularly for women who do not take hormone therapy. The metabolic changes described above are well documented at the population level, but prospective studies that follow women through the full transition are still relatively rare, which limits how precisely clinicians can predict any one woman’s trajectory.
What is clear is that the variability is normal, not a signal that something is wrong.
Perimenopause is a transition most women will experience, but how it feels, how long it lasts, and what helps are individual questions that deserve individual answers — not a one-size-fits-all protocol.